Is compounded semaglutide or tirzepatide FDA-approved?

No: as of October 15, 2026, compounded semaglutide and compounded tirzepatide are not FDA-approved, are not generic drugs and are not the same products as Ozempic, Wegovy, Mounjaro or Zepbound, because FDA does not review compounded preparations for safety, effectiveness or quality before they are sold. Licensed 503A pharmacies may compound them for an individual patient with a prescription. FDA has proposed keeping both drugs off the 503B bulks list; comments closed July 30, 2026, and no final decision had been published by October 15.

Compounded vs Brand-Name Semaglutide

Compounded vs Brand-Name Semaglutide

Released: June 1, 2026Last reviewed: November 6, 2026

Made with the drug in Wegovy and Ozempic, not the same product. Brand: FDA-approved; Wegovy is $349/mo through NovoCare self-pay and the Wegovy pill $149–$299/mo (read October 15, 2026). Compounded: not FDA-approved; month-to-month examples include $87 (Mondae) and $99 (Eden), read October 15, 2026, and $109 (NexLife, as of November 6, 2026). Ask the pharmacy what testing it performs on each batch.

Educational

Researched By

Dr. Parmis

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Compounded vs Brand-Name Semaglutide

Overview

Related guides